FDA DEVICE FACTS
TRAQinform IQ
AIQ Global, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
TRAQinform IQ is a software only device that provides a quantitative TRAQinform Report on lesions identified as Regions of Interest (ROI) in PET/CT DICOM compliant imaging data acquired, interpreted, and reported on per local practice prior to device use. Clinicians responsible for patient care and for ordering TRAQinform Reports as an adjunct to locally reported image interpretation do not interact directly with the device. Clinicians responsible for local image interpretation do not interact with the device and generate their reporting before and independently of the TRAQinform Report. The TRAQinform Report is generated by the device manufacturer and signed by a U.S. board certified physician responsible for supervising central report generation and qualified to practice nuclear radiology/medicine. The TRAQinform Report is for use by trained medical professionals including but not limited to oncologists, nuclear radiologists/physicians, medical imaging technologists, dosimetrists, and physicists. TRAQinform IQ software contains the following functionalities:
• Automated matching of ROI between previously performed CT and PET/CT DICOM 3.0 volumetric medical images.
• In order to perform automated matching of ROI and quantitative analysis of previously performed CT and PET/CT DICOM 3.0 volumetric medical images, the software initially performs the following functions:
• Machine learning skeletal and anatomic structure segmentation.
• Threshold-based ROI identification and contouring.
• Automated quantitative analysis to assess previously performed CT and PET/CT DICOM 3.0 volumetric medical images, including: change in total volume and density of each identified ROI, and change in Fludeoxyglucose F18 (FDG) tracer uptake of each identified ROI among images.
• Generation of images of the anatomy combined with spatial and quantitative information, including computed classification of quantitative FDG ROI changes. For multi-timepoint quantitative analysis, recommended use is in adult patients 22 years and older with partial or whole-body PET/CT acquired following administration of FDG per approved drug prescribing information and with the second FDG administration separated from the first by a period not to exceed 12 months. For single-timepoint quantitative analysis, recommended use is in adult patients 22 years and older with partial or whole-body PET/CT following administration of FDG, a PSMA targeted PET drug, or a SSTR-targeted PET drug per approved drug prescribing information. Discrepancies between TRAQinform IQ and local PET/CT reporting have been investigated and use of TRAQinform IQ has not been established for binary patient level progression or non-progression decisions without multidisciplinary review. Discrepancies between TRAQinform IQ and local PET/CT reporting that could impact patient care should therefore prompt consultation with subject matter experts (for example, in tumor board), with a patient-centered focus on discrepant imaging regions and with blinded or otherwise neutral adjudication regarding interpretation/classification source. TRAQinform IQ is not intended to diagnose any disease, replace the diagnostic procedures for interpretation of CT or PET/CT images, recommend any specific treatment, nor is it intended to replace the skill and judgment of a qualified medical professional.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。